Also from this source

You just read:

Arcturus Therapeutics, Inc. Announces an RNAi Therapeutic Targeting Transthyretin-mediated Amyloidosis as its Flagship Program

News provided by

Arcturus Therapeutics, Inc.

Jan 13, 2014, 04:00 EST